Switching maintenance infliximab therapy to biosimilar infliximab in inflammatory bowel disease patients.

about

Switching from originator infliximab to the biosimilar CT-P13 in 313 patients with inflammatory bowel disease Non-medical Switching from Originator Tumor Necrosis Factor Inhibitors to Their Biosimilars: Systematic Review of Randomized Controlled Trials and Real-World Studies

P2860

Q57816058-01370387-AA94-49F0-9688-6E4C1FAD7FBD Q58798380-B1F54A3E-A763-45BD-8550-B0144FBC1320

P2860

Switching maintenance infliximab therapy to biosimilar infliximab in inflammatory bowel disease patients.

Item

http://www.wikidata.org/entity/Q38609741

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年論文

@yue

2017年論文

@zh-hant

2017年論文

@zh-hk

2017年論文

@zh-mo

2017年論文

@zh-tw

2017年论文

@wuu

2017年论文

@zh

2017年论文

@zh-cn

name

Switching maintenance inflixim ...... matory bowel disease patients.

@en

type

Item

label

Switching maintenance inflixim ...... matory bowel disease patients.

@en

prefLabel

Switching maintenance inflixim ...... matory bowel disease patients.

@en

P1476

Switching maintenance inflixim ...... matory bowel disease patients.

@en

P2093

Anja Eberl

http://www.w3.org/2001/XMLSchema#string

Marja Blom

http://www.w3.org/2001/XMLSchema#string

Perttu Arkkila

http://www.w3.org/2001/XMLSchema#string

Saara Huoponen

http://www.w3.org/2001/XMLSchema#string

Taina Sipponen

http://www.w3.org/2001/XMLSchema#string

Tapio Pahikkala

http://www.w3.org/2001/XMLSchema#string

P2860

Infliximab for induction and maintenance therapy for ulcerative colitis

Effectiveness and Safety of CT-P13 (Biosimilar Infliximab) in Patients with Inflammatory Bowel Disease in Real Life at 6 Months.

Effectiveness of concomitant immunosuppressive therapy in suppressing the formation of antibodies to infliximab in Crohn's disease.

The relationship between infliximab concentrations, antibodies to infliximab and disease activity in Crohn's disease.

A randomised, double-blind, parallel-group study to demonstrate equivalence in efficacy and safety of CT-P13 compared with innovator infliximab when coadministered with methotrexate in patients with active rheumatoid arthritis: the PLANETRA study.

A randomised, double-blind, multicentre, parallel-group, prospective study comparing the pharmacokinetics, safety, and efficacy of CT-P13 and innovator infliximab in patients with ankylosing spondylitis: the PLANETAS study

Assessing response and loss of response to biological therapies in IBD.

Fecal calprotectin in diagnosis and clinical assessment of inflammatory bowel disease.

Pharmacokinetics of anti-TNF monoclonal antibodies in inflammatory bowel disease: Adding value to current practice.

Safety and efficacy of maintenance infliximab therapy for moderate-to-severe Crohn's disease in children: REACH open-label extension.

P304

1-6

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1080/00365521.2017.1369561

http://www.w3.org/2001/XMLSchema#string

P577

2017-08-24T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28838273

http://www.w3.org/2001/XMLSchema#string

Switching maintenance infliximab therapy to biosimilar infliximab in inflammatory bowel disease patients.

about

P2860

P2860

Switching maintenance infliximab therapy to biosimilar infliximab in inflammatory bowel disease patients.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P577

P698

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P577

P698